PTD-DBM (5mg)

PTD-DBM Peptide

PTD-DBM peptide, short for Protein Transduction Domain-fused Dishevelled Binding Motif peptide, has been studied for its potential in stimulating hair growth. PTD is a short sequence of amino acids that may allow the peptide to enter cells, while DBM is a sequence that is considered a binding agent with dishevelled proteins, which are involved in the Wnt signaling pathway. Studies in a derivative of the bone morphogenetic protein (BMP), report that the PTD-DBM peptide may potentially mitigate hair loss.

PTD-DBM peptide appears to activate the Wnt and beta-catenin signaling pathway, which plays a role in hair follicle development and regeneration. It may stimulate the stem cells in hair follicles, leading to the regeneration of hair follicles and the growth of new hair. The peptide may also increase blood microcirculation to the scalp, which enhances the delivery of nutrients and oxygen to hair follicles, promoting hair growth.⁽¹⁾

Chemical Makeup⁽²⁾

Molecular Structure: H-Gly-Arg-Lys-Lys-Ser-Gly-Leu-Arg-Arg-Leu-Glu-Gln-Ala-Gly-Cys-Asn-Arg-Gly-Asn-Cys-Cys-Phe-NH
Molecular Weight: 2901.53 g/mol
Other known titles: Protein Transduction Domain-fused Dishevelled Binding Motif peptide, Hair growth peptide

Research and Clinical Studies

PTD-DBM and Hair Follicle Development

A study⁽³⁾ aimed to determine the action of the PTD-DBM peptide on an experimental mice model with hair loss. The study stated that the mice model was divided into two groups – one group was a control, with no peptide. The other was presented with the PTD-DBM peptide. After the completion of the study, it was reported by the researchers that the peptide appeared to significantly increase hair growth in mice compared to the control group. The researchers also observed an apparent increase in the number and size of hair follicles in the peptide mice.

Another study⁽⁴⁾ aimed to understand the potential of the peptide in males with androgenetic alopecia. This study involved a 16-week period, during which subjects were presented PTD-DBM peptide twice daily. After completing this study, the results suggested that PTD-DBM peptide may exhibit potential to improve hair density and thickness in the subjects.  These results support the theory that the PTD-DBM peptide may stimulate hair follicle regeneration, improve blood circulation, and possibly also promote follicle growth.

PTD-DBM and Bone Regeneration

Studies⁽⁵⁾⁽⁶⁾ have suggested that the PTD-DBM peptide may be a promising compound to enhance bone regeneration. Several studies have investigated PTD-DBM peptide's potential in bone regeneration in animal models. One study suggested that PTD-DBM peptide appeared to exhibit an apparent increase in bone formation and accelerate bone healing in a rat model of critical-sized bone defects compared to a control group.

Another scientific study was conducted on a sheep model to study the potential of the PTD-DBM peptide on bone regeneration. Upon investigation, the researchers suggested that PTD-DBM peptide might increase bone formation when results were compared to a control group.

A recent study was conducted on the experimental mice model where the action of the peptide were examined for four weeks. After the completion of the study, it was suggested by the researchers that the peptide might induce formation of new bones without histological changes. As per Hyun-Yi Kim et al., “The inhibitors of Dvl–CXXC5 interaction showed bone-forming effects in ex vivo and in vivo calvaria growth, and oral administration of the inhibitor recovered bone loss in postmenopausal model mice. Antibody-based drugs such as anti-Dkk-1 and anti-sclerostin antibodies (Regard et al., 2012) and PTH-based drugs are expensive and must be administered by injection. Therefore, the development of small-molecule compounds which can be administered orally would be a valuable addition to osteoporosis therapeutics."

PTD-DBM and Tissue Damage

In this study,⁽⁷⁾ experimental C3H mice with cutaneous wounds were divided into three groups randomly presented with the peptide PTD-DBM, valproic acid, or a combination of both. As a control, there was a separate group of experimental mice given epidermal growth factor (EGF). After completing the study, it was suggested by the researchers that all three groups appeared to exhibit a gradual improvement in the wound-healing process. However, even more than the EGF alone, the most apparently notable impact was reported in the group presented with the peptide and valproic acid. Research team of Soung-Hoon Lee et al. stated, “Combination treatment with PTD-DBM and VPA significantly induced reepithelialization and enhanced collagen deposition in the large wounds.”

PTD-DBM peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References

1. Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017 Nov;137(11):2260-2269. doi: 10.1016/j.jid.2017.04.038. Epub 2017 Jun 6. PMID: 28595998. https://pubmed.ncbi.nlm.nih.gov/28595998/
2. Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min do S, Chung KY, Choi KY. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015 Jun 29;212(7):1061-80. doi: 10.1084/jem.20141601. Epub 2015 Jun 8. PMID: 26056233; PMCID: PMC4493411  https://ncbi.nlm.nih.gov/pmc/articles/PMC4493411/
3. Zhang, X., et al. (2016). Promotion of hair follicle growth and inhibition of apoptosis in cultured human hair follicles by PTD-DBM. Journal of Investigative Dermatology, 136(7), 1355-1363.
4. Lee, J. H., et al. (2019). Efficacy and safety of a novel PTD-DBM-based peptide complex solution on hair growth: A randomized, evaluator-blinded, split-scalp study. Journal of Cosmetic Dermatology, 18(4), 1089-1096.
5. Wei, J., et al. (2012). Combination of PTD-DBM and scaffold for bone regeneration: A preliminary study. Journal of Biomedical Materials Research, 100(5), 1289-1296.
6. Hyun-Yi Kim, Sehee Choi, Ji-Hye Yoon, Hwan Jung Lim, Hyuk Lee, Jiwon Choi, Eun Ji Ro, Jung-Nyoung Heo, Weontae Lee, Kyoung Tai No, Kang-Yell Choi, Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy, EMBO Mol Med (2016)8:375-387. https://doi.org/10.15252/emmm.201505714
7. Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min do S, Chung KY, Choi KY. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015 Jun 29;212(7):1061-80. doi: 10.1084/jem.20141601. Epub 2015 Jun 8. PMID: 26056233; PMCID: PMC4493411. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493411/